On May 12, 2014, MannKind Corporation (NASDAQ:MNKD), reported its Q1 2014 financial results. Net loss applicable to common stockholders were $52.1 million, or $0.14 per diluted share, compared to $41.0 million, or $0.15 per diluted share in Q1 2013. Research and development (R&D) expenses were $26.2 million, compared to $26.4 million in Q1 2013. No revenues were reported for the quarter by the Company. As of March 31, 2014, the Company had cash and cash equivalents of $35.8 million. MannKind Corporation (NASDAQ:MNKD), weekly performance is 15.05%. On last trading day company shares ended up $7.57. Analysts mean target price for the company is $8.07. MannKind Corporation (NASDAQ:MNKD), distance from 50-day simple moving average (SMA50) is 23.09%.
Gilead Sciences, Inc. (NASDAQ:GILD), announced results from a placebo-controlled, Phase 2a challenge study in healthy adult patients intranasally infected with respiratory syncytial virus (RSV). The study of GS-5806, an investigational oral RSV fusion inhibitor, achieved its primary and secondary endpoints of lower viral load (the amount of virus detected in the nasal wash), improvements in total mucus weight (the amount of mucus produced by the nose) and also symptom diary score compared to placebo. Detailed results from this study (Poster #1008) will be presented during a poster discussion session at the American Thoracic Society 2014 International Conference in San Diego. Gilead Sciences, Inc. (NASDAQ:GILD), fell 1.11% in last trading session and ended the day on $81.14. GILD, Gross Margin is 77.80% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD), quarterly performance is -1.89%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), fell 6.3% after the company reported a net loss per share of 12 cents in the Q1 of 2014. Arena had incurred a narrower loss of 9 cents in the year-ago quarter. Arena Pharma recorded Q1 revenues of $2.9 million benefiting from revenues recorded for its obesity drug, Belviq. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), shares moved down 2.69% in last trading session and was closed at $6.33, while trading in range of $6.31 – 6.72. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), year to date (YTD) performance is 8.21%.
On May 14, 2014, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), announced that clinical data on Iclusig (ponatinib) and AP26113, its investigational oral inhibitor of anaplastic lymphoma kinase (ALK), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 30 to June 3, 2014. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), ended the last trading day at $6.36. Company weekly volatility is calculated as 4.60% and price to cash ratio as 5.01. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), showed a negative weekly performance of 4.65%.
An investor, who currently holds shares of Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), filed a lawsuit in effort to halt the takeover of Chelsea Therapeutics International Ltd. by H. Lundbeck A/S for a value of up to $7.94 per share. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), weekly performance is -1.21%. On last trading day company shares ended up $6.53. Analysts mean target price for the company is $9.50. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), distance from 50-day simple moving average (SMA50) is 17.74%.
Leave a Reply